Novel applications of immunotherapies and vaccines beyond prevention and
treatment of infectious diseases and cancer are reviewed. Those discussed
typically target molecules not normally targeted by the immune system.
This report:
Covers a wide range of conditions for which immunotherapies may be effective,
including Alzheimer' s disease, addiction, other neurological indications,
cardiovascular diseases, hematological disorders, ophthalmic diseases, bone
metabolism disorders, type 2 diabetes, among others Reviews emerging
immunotherapies and vaccines for these indications as well as business
considerations for companies active in these markets Includes expert
interviews Applications of immunotherapies and vaccines for prevention and
treatment of infectious diseases and cancer are well known. Research and
development of immunotherapies for other indications has been progressing for
many years, although this effort has not received the public attention that
the work on infectious disease and cancer immunotherapies and vaccines has.
Immunotherapies being developed or used for treatment of other diseases (i.e.,
beyond prevention and treatment of infectious diseases and cancer) are the
focus of this report. These may work by different mechanisms of action, and
available information regarding how these immunotherapies work is presented.
Each chapter focuses on one disease or disease category, which include
Alzheimer' s disease, cocaine and nicotine addiction, other neurology
applications including pain, cardiovascular diseases including thrombosis,
hematology/blood disorders, ophthalmology, osteoporosis and other bone
metabolism disorders, type 2 diabetes, and other (general) applications of
immunotherapies.
For each disease or field covered, Immunotherapies and Vaccines for
Nontraditional Indications provides information on pathophysiology,
epidemiology, and currently available pharmacological treatments. This is
followed by a discussion of what is being targeted by immunotherapies and/or
vaccines for these diseases, and why immunotherapies may be effective for
treatment of these conditions. Immunotherapies and vaccines that are in
development or are approved for that particular indication are reviewed, and
business considerations for companies that are active in these markets are
discussed.
The use of immunotherapies for treatment of these diseases is a very promising
field. While it will vary with the different disease indications, some of
these immunotherapies and vaccines have a potentially large market
opportunity. For example, the current market for Alzheimer' s disease therapies
already exceeds $4 billion annually worldwide, and these therapies treat only
the symptoms of the disease. This market is likely to grow significantly if
more effective therapies become available.
Immunotherapies and Vaccines for Nontraditional Indications concludes by
providing complete transcripts of interviews with experts from the field, who
discuss its progress, challenges, and hurdles.
Table of Contents
Table of Contents
1.1. The Immune System
1.2. Scope of the Report
Chapter 2 ALZHEIMER' S DISEASE
2.1. Alzheimer' s Disease Pathophysiology, Epidemiology, and Current
Treatments
2.2. Why Immunotherapies or Vaccines for Treatment of Alzheimer' s Disease?
2.3. Companies Developing Immunotherapies or Vaccines for Alzheimer' s
Disease
AFFiRiS
Baxter
Novartis and Cytos Biotechnology
Eli Lilly
Genentech and AC Immune
GlaxoSmithKline
Merck & Co.
Octapharma
Pfizer
Roche and MorphoSys
Wyeth and Elan
2.4. Business Considerations: Immunotherapies for Alzheimer' s Disease
Chapter 3 ADDICTION
3.1. Pathophysiology, Epidemiology, and Current Treatments
Cocaine Addiction
Nicotine Addiction (Smoking Cessation)
3.2. Why Immunotherapies for Addiction?
3.3. Companies Developing Immunotherapies for Cocaine Addiction or Smoking
Cessation
Cocaine Addiction
Celtic Pharma
Nicotine Addiction (Smoking Cessation)
Celtic Pharma
Nabi Biopharmaceuticals
Novartis and Cytos Biotechnology
3.4. Business Considerations: Immunotherapies for Cocaine Addiction or
Smoking Cessation
Chapter 4 OTHER NEUROLOGY INDICATIONS FOR MONOCLONAL ANTIBODIES AND IMMUNOTHERAPIES
4.1. Pathophysiology, Epidemiology, and Current Treatments
Multifocal Motor Neuropathy
Pain
Post-Polio Syndrome
Other Potential Neurology Indications
4.2. Why Immunotherapies for Treatment of Pain?
4.3. Companies Developing or Marketing Immunotherapies for Other
Neurological Indications
Alexion Pharmaceuticals' Soliris (eculizumab)
Array BioPharma' s ARRY-797
Baxter' s Immune Globulin
CSL Behring' s Immune Globulin
GlaxoSmithKline' s 249320 (GSK249320)
Pfizer' s Tanezumab
Pharmalink' s Xepol (XP-28)
Talecris Biotherapeutics' Gamunex
4.4. Business Considerations: Immunotherapies for Other Neurological
Indications
Chapter 5 CARDIOVASCULAR DISEASES INCLUDING THROMBOSIS
5.1. Pathophysiology, Epidemiology, and Current Treatments
Angina
Atherosclerosis
Dyslipidemia (Elevated Cholesterol and Other Lipids)
Hypertension
Venous Thromboembolism
Digoxin Toxicity
5.2. Why Immunotherapies for Selected Cardiovascular Diseases?
5.3. Companies Developing Immunotherapies for Cardiovascular Diseases
Ablynx' ALX-0081 and ALX-0681
BTG' s DigiFab
BTG' s Angiotensin Therapeutic Vaccine
Centocor Ortho Biotech' s and Eli Lilly' s ReoPro (abciximab)
Cytos Biotechnology' s CYT006-AngQb
Genentech' s and BioInvent International' s BI-204 (anti-oxLDL)
GlaxoSmithKline' s Digibind
Roche' s and Genmab' s R1512
ThromboGenics' and BioInvent International' s TB-402
5.4. Business Considerations: Immunotherapies for Cardiovascular Diseases
Chapter 6 HEMATOLOGY/BLOOD DISORDERS
6.1. Pathophysiology, Epidemiology, and Current Treatments
11.7. Walter Schmidt, PhD; Chief Executive Officer; AFFiRiS
References
Company Index with Web Addresses
Immunotherapies and Vaccines for Nontraditional Indications published by Insight Pharma Reports in October 6, 2009. This report price starts from US $ 3195.
